NewsRoom Articles - Page 28 of 208

ThursdayJul 18, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction

Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a treatment for ALS via the accelerated approval process The briefing book includes new post-hoc analyses of data from completed clinical trials and addresses comments made by the FDA during a previous meeting in late 2023 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage…

WednesdayJul 17, 2024 10:00 am

Women with Autism Have Higher Odds of Being Misdiagnosed with BPD

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that has been identified to occur at different levels of severity. Patients with this disorder are sometimes misdiagnosed, because its symptoms overlap with other disorders. It is said that women are less likely to be accurately diagnosed with autism during their lifetimes, with most being misdiagnosed with borderline personality disorder (BPD) or other disorders before they are diagnosed with autism. A possible explanation is that young girls learn how to fit in and get along with others early. Focusing on social interaction may enable them to camouflage their autism symptoms, which keeps…

WednesdayJul 17, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is…

MondayJul 15, 2024 10:00 am

Study Suggests Vitamin B Deficiency Could Be Pivotal in Parkinson’s Disease

Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease. This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubling since 1990. The risk of developing this condition heightens with age; in addition, men are 50% more likely than women to develop the disease. Other risk factors include past traumatic brain injury, exposure to environmental toxin and genetics. Primary symptoms of the condition include muscle stiffness, tremors, impaired coordination and balance, gastrointestinal symptoms and emotional changes, among others. Prior…

FridayJul 12, 2024 10:00 am

Study Explores Starving Malignant Cells to Boost Immunotherapy, Improve DNA Damage

Prostate cancer is challenging to treat, especially when the disease progresses to a castrate-resistant metastatic state. Conventional treatments, such as hormonal treatments, radiotherapy and chemotherapy, fail most times because of acquired resistance, off-target effects and toxicities. It is well-known that amino acids perform important metabolic functions. While normal cells have lower demand for amino acids, cancer cells exhibit high demand for amino acids because of increased demand for cellular building blocks and energy. Now a new study has determined that starving cancer cells may help improve immunotherapy response and increase damage to DNA, which in turn helps speed up death…

WednesdayJul 10, 2024 10:00 am

30 Years Later, Amazon Now Dominates eCommerce

On July 5,1994, Jeff Bezos founded Amazon as a bookselling business in his garage. Three decades later, Amazon is one the largest companies globally. The company’s value currently stands at $2.08 trillion. Let’s look at the company’s trajectory, from the beginning to its current position in the global markets. Who was Bezos prior to founding Amazon? In 1994, Bezos was a Wall Street investment banker who wanted to be part of the dot.com boom. He was focused and intense, despite being a frugal individual who drove a Honda and wore khakis. His objective was to build a store that carried…

MondayJul 08, 2024 12:00 pm

Astiva Health Inc. Leading the Way as Record Number of People Choose Medicare Advantage Plans

For the first time in Medicare’s history, more than half of all eligible people with Medicare are enrolled in private Medicare Advantage plans Enrollment in Medicare Advantage programs is projected to grow from 54% of the eligible population in 2024 to 60% by the end of the decade Astiva Health has developed one of the most diverse networks in Southern California and offers a selection of benefits tailored to the specialized needs of its members According to a recent KFF report, a record number of people enrolled in private Medicare Advantage plans last year (https://ibn.fm/YEpRJ). That trend bodes well for Astiva Health,…

MondayJul 08, 2024 10:00 am

Research Identifies How Glioblastoma Develops Resistance to Immunotherapy

Glioblastoma multiforme is an aggressive cancer that grows quickly and spreads rapidly, originating as a growth of cells in the spinal cord or the brain. Researchers at the University of Copenhagen may have discovered how this type of cancer, which primarily effects adults, develops resistance to immunotherapy. At first, the researchers thought that the cancer cells changed their DNA via mutation, helping them become treatment resistant. However, the researchers observed that when glioblastoma cells were subjected to immunotherapy, they behaved differently. Joachim Lütken Weischenfeldt, a clinical professor at the Biotech Research and Innovation Center, led this research. For their study,…

FridayJul 05, 2024 10:00 am

Study Suggests AI Models Could Be Relying on ‘Demographic Shortcuts’ During Medical Diagnosis

New research has determined that artificial intelligence (AI) models may be depending on “demographic shortcuts” when making medical diagnoses. Prior studies had determined that these models could reliably predict a patient’s race from their chest X-rays, something even the best radiologists couldn’t do. This has been further put under the spotlight by this recent study, which determined that these artificial intelligence models have discrepancies in their ability to reliably diagnose images of individuals of different races or genders. For their study, the researchers used chest X-ray datasets to train the models to predict if patients either suffered from a collapsed…

FridayJul 05, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome Treatment

Clene revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado The only current FDA-approved drug for Rett Syndrome is trofinetide, approved in 2023 CNM-Au8 treatment showed improvements in mitochondrial respiration deficits in Rett patient-derived astrocytes Clene (NASDAQ: CLNN), along with its subsidiary Clene Nanomedicine Inc., a biopharmaceutical company specializing in mitochondrial health to address neurological diseases like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment. The data was presented by Dr. Karen Ho, Clene’s Vice President…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction

Women with Autism Have Higher Odds of Being Misdiagnosed with BPD

Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

Study Suggests Vitamin B Deficiency Could Be Pivotal in Parkinson’s Disease

Study Explores Starving Malignant Cells to Boost Immunotherapy, Improve DNA Damage

30 Years Later, Amazon Now Dominates eCommerce

Astiva Health Inc. Leading the Way as Record Number of People Choose Medicare Advantage Plans

Research Identifies How Glioblastoma Develops Resistance to Immunotherapy

Study Suggests AI Models Could Be Relying on ‘Demographic Shortcuts’ During Medical Diagnosis

Clene Inc. (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome Treatment

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search